While NLRP3 inflammasome-induced neuroinflammation plays a crucial role in dopaminergic neuronal degeneration in Parkinson's disease (PD), agonist treatment of PPARß/δ (GW501516) could suppress NLRP3 inflammasome activation in the midbrain of MPTP-induced mouse model of PD. This evidence concerns the gene NLRP3 and Parkinson disease.